Key result
Disruption or inhibition of 12/15-LOX improved STZ-induced cardiac dysfunction and fibrosis by reducing inflammation and oxidative stress in diabetic mice.
Why the study?
Does inhibition or deletion of 12/15-LOX improve cardiac dysfunction and fibrosis in models of diabetic cardiomyopathy?
Does inhibition or deletion of 12/15-LOX improve cardiac dysfunction and fibrosis in models of diabetic cardiomyopathy?
Inhibition of 12/15-LOX reduces inflammation and oxidative stress, improving cardiac dysfunction and fibrosis in preclinical models of diabetic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Supports 12/15-LOX inhibition in preclinical diabetic cardiomyopathy; leaves open applicability to patients.
Diabetes affects cardiac structure and function, and it has been suggested that diabetes leads to cardiomyopathy. Arachidonate 12/15-lipoxygenase (LOX) has been suggested to play an important role in atherogenesis and heart failure. However, the role of 12/15-LOX in diabetic cardiomyopathy has not been examined. In this study, we investigated the effects of cardiac 12/15-LOX on diabetic cardiomyopathy. We created streptozotocin (STZ)-induced diabetic mice and compared them with Alox15-deficient mice. Expression of 12/15-LOX and inflammatory cytokines such as tumor necrosis factor (TNF)-α and nuclear factor (NF)-κB were upregulated in STZ-induced diabetic hearts. Disruption of 12/15-LOX significantly improved STZ-induced cardiac dysfunction and fibrosis. Moreover, deletion of 12/15-LOX inhibited the increases of TNF-α and NF-κB as well as the production of STZ-induced reactive oxygen species in the heart. Administration of N-acetylcysteine in diabetic mice prevented STZ-induced cardiac fibrosis. Neonatal cultured cardiomyocytes exposed to high glucose conditions induced the expression of 12/15-LOX as well as TNF-α, NF-κB, and collagen markers. These increases were inhibited by treatment of the 12/15-LOX inhibitor. Our results suggest that cardiac 12/15-LOX-induced inflammation and oxidative stress are involved in the development of diabetic cardiomyopathy and that inhibition of 12/15-LOX could be a novel treatment for this condition.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2014) studied Diabetic cardiomyopathy. 12/15-LOX disruption or inhibition vs. Wild-type STZ-induced diabetic mice or untreated controls was evaluated on Cardiac dysfunction, fibrosis, inflammation, and oxidative stress. Disruption or inhibition of 12/15-LOX improved STZ-induced cardiac dysfunction and fibrosis by reducing inflammation and oxidative stress in diabetic mice.
Synapse has enriched 10 related papers. Consider them for comparative context: